Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors

T cell Receptor (TCR) Fusion Construct (TRuC®) T cells harness all signaling subunits of the TCR to activate T cells and eliminate tumor cells, with minimal release of cytokines. While adoptive cell therapy with chimeric antigen receptor (CAR)-T cells has shown unprecedented clinical efficacy agains...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Jian, Guyette, Sarah, Schrand, Brett, Geirut, Jessica, Horton, Holly, Guo, Guangwu, Delgoffe, Greg, Menk, Ashley, Baeuerle, Patrick A., Hofmeister, Robert, Tighe, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980471/
https://www.ncbi.nlm.nih.gov/pubmed/36875551
http://dx.doi.org/10.1080/2162402X.2023.2182058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980471/
https://www.ncbi.nlm.nih.gov/pubmed/36875551
http://dx.doi.org/10.1080/2162402X.2023.2182058

Ejemplares similares